Naohisa Arakawa
Overview
Explore the profile of Naohisa Arakawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murasawa H, Kobayashi H, Yasuda S, Saeki K, Domon Y, Arakawa N, et al.
Pharmacol Rep
. 2020 Apr;
72(3):571-579.
PMID: 32270470
Background: Mental disorders including anxiety and depression are common comorbidities in fibromyalgia patients, and exert a profound impact on their quality of life. Mirogabalin, a novel ligand for the αδ-subunit...
2.
Saeki K, Yasuda S, Kato M, Kano M, Domon Y, Arakawa N, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2019 Feb;
392(6):723-728.
PMID: 30770951
Mirogabalin, a novel ligand for the αδ subunit of voltage-gated calcium channels, is under the development for the treatment of neuropathic pain. Mirogabalin specifically and potently binds to αδ subunits,...
3.
Shimada K, Ohata Y, Kobayashi J, Onishi Y, Kawamura A, Domon Y, et al.
Bioorg Med Chem Lett
. 2018 May;
28(11):2000-2002.
PMID: 29752183
We identified novel (3R, 5S)-3-aminomethyl-5-methanesulfanyl hexanoic acid (5a: DS75091588) and (3R, 5S)-3-aminomethyl-5-ethanesulfanyl hexanoic acid (6a: DS18430756) as sulfur-containing γ-amino acid derivatives that were useful for the treatment of neuropathic pain....
4.
Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al.
J Pharmacol Exp Ther
. 2018 Mar;
365(3):573-582.
PMID: 29563324
Mirogabalin ([(1,5,6)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid), a novel ligand for the subunit of voltage-gated calcium channels, is being developed to treat pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. In the present...
5.
Navratilova E, Xie J, Meske D, Qu C, Morimura K, Okun A, et al.
J Neurosci
. 2015 May;
35(18):7264-71.
PMID: 25948274
Pain is aversive, and its relief elicits reward mediated by dopaminergic signaling in the nucleus accumbens (NAc), a part of the mesolimbic reward motivation pathway. How the reward pathway is...
6.
Nakamura H, Domon Y, Inoue T, Arakawa N, Yokoyama T
Neuroreport
. 2009 Sep;
20(16):1481-5.
PMID: 19786922
To evaluate the effect of angiotensin II type1 receptor blocker on nerve regeneration delay in diabetic rats, nerve regeneration was monitored by a pinch test on the crushed sciatic nerves...
7.
Nakamura H, Yamazaki M, Ohyama T, Inoue T, Arakawa N, Domon Y, et al.
Ophthalmic Res
. 2009 May;
41(4):210-5.
PMID: 19451734
Aim: To investigate the role of angiotensin type 1 (AT1) and type 2 (AT2) receptors in hypoxia-induced retinal vascular hyperpermeability. Methods: Brown-Norway rat pups were exposed to hyperoxic conditions from...
8.
Hirose M, Hashimoto H, Iga J, Shintani N, Nakanishi M, Arakawa N, et al.
Ann N Y Acad Sci
. 2006 Aug;
1070:342-7.
PMID: 16888189
Several lines of evidence have suggested roles for pituitary adenylate cyclase-activating polypeptide (PACAP) in the developing nervous system. Previously, we showed that mRNA for PACAP, vasoactive intestinal peptide (VIP), and...
9.
Nakamura H, Inoue T, Arakawa N, Shimizu Y, Yoshigae Y, Fujimori I, et al.
Eur J Pharmacol
. 2005 Apr;
512(2-3):239-46.
PMID: 15840410
A close relationship between the renin-angiotensin system and the pathophysiology of diabetic retinopathy has been suggested, several angiotensin II type 1 receptor (angiotensin AT1 receptor) antagonists being effective in animal...
10.
Hirose M, Hashimoto H, Shintani N, Nakanishi M, Arakawa N, Iga J, et al.
Regul Pept
. 2004 Dec;
126(1-2):109-13.
PMID: 15620423
The expressions of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), and their receptors (PAC1, VPAC1 and VPAC2) were examined in the five steps of the in...